Genmab invests heavily in artificial intelligence
”We believe that AI and access to more information digitally can help us in all parts of our business,” says Jan van de Winkel, CEO of Genmab.
By MarketWire
Artificial Intelligence, AI, is very much on the radar at Genmab, which is investing heavily in the new possibilities in the expectation that it will, among other things, shorten the path to market for new drugs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk launches its own version of ChatGPT
For subscribers
GPT AI has arrived in the doctor's office
For subscribers
